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Background: HIF-1α and CXCR4/CXCL12 have crucial roles in the metastatic process of colorectal cancer. Our aim
was to study the significance of targeting HIF-1α and the CXCR4/CXCL12 axis in colorectal cancer to prevent the
dissemination process in vitro.
Methods: We investigated CXCR4 and CXCR7 mRNA and protein expression in human colon carcinomas and the
modulation of their expression by hypoxia and HIF-1α in colon cancer cell lines. The migration of tumor cells in a
Boyden chamber was studied after CXCR4 inhibition with siRNA or the CXCR4/CXCL12 neutraligand, chalcone 4.
Results: Analysis of a cohort of colon polyps and chromosome-unstable carcinomas showed that the expression of
CXCR4 and CXCR7 was similar to that of the normal mucosa in the polyps and early-stage carcinomas but significantly
increased in late stage carcinomas. Our data demonstrate that hypoxia strongly induced the expression of CXCR4
transcript and protein at the cell membrane, both regulated by HIF-1α, whereas CXCR7 expression was independent of
hypoxia. After transient hypoxia, CXCR4 levels remained stable at the cell membrane up to 48 hours. Furthermore,
reducing CXCR4 expression impaired CXCL12-induced Akt phosphorylation, whereas Erk activation remained unchanged.
In contrast, reducing CXCR7 expression did not affect Akt nor Erk activation. In the presence of CXCR4 or CXCR7 siRNAs, a
significant reduction in cell migration occurred (37% and 17%, respectively). Although irinotecan inhibited cell migration
by 20% (p <0.001), the irinotecan and chalcone 4 combination further increased inhibition to 40% (p <0.001).
Conclusion: We demonstrated, for the first time, that hypoxia upregulated CXCR4 but not CXCR7 expression in tumor
cells and that the CXCR4 receptor protein level remains high at the cell membrane when the tumor cells return to
normoxia for up to 48 hours. In addition we showed the interest to inhibit the CXCR4 signaling by inhibiting both the
HIF-1α and CXCR4/CXCL12 pathway. CXCR4 seems to be a relevant target because it is continuously expressed and
functional both in normoxic and hypoxic conditions in tumor cells.
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Tumor progression is associated with intratumoral hyp-
oxia, which leads to an increase in vascular density. The
increased vascular density often exhibits an abnormal
architecture and provides heterogeneous perfusion within
the tumor tissue [1]. HIF-1α is a transcription factor that
permits the adaptation of tumor cells to changing* Correspondence: dominique.guenot@inserm.fr
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unless otherwise stated.environment, such as hypoxia [2]. Many studies have
shown that HIF-1α is overexpressed at very high levels
in colorectal tumors, particularly in the most aggressive
tumors [3]. HIF-1α protein plays a major role in regulating
the expression of many genes involved in angiogen-
esis and erythropoiesis, metabolic adaptation to hypoxia,
epithelial-mesenchymal transition (EMT), extracellular ma-
trix degradation and chemotaxis through CXCR4 and the
CXCL12/SDF-1 axis [4].
The expression of chemo-attractant molecules and their
receptors (such as CXCL12-SDF1/CXCR4 and VEGF/
VEGFRs) induces tumor cell dissemination from primitive
tumor sites to metastatic niches. In many tumor models,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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microenvironment and the recruitment of hematopoietic
and endothelial progenitors for neovascularization [5]. In-
terestingly, recent studies have shown that overexpressions
of the chemokine receptor CXCR4 and of VEGF were pre-
dictive of early distant relapse in stages II and III colorec-
tal cancers [6]. CXCR4 is a highly conserved G protein
coupled receptor (GPCR) that binds CXCL12. Although
CXCR4 is expressed in a wide range of tissues, its expres-
sion is low or absent in normal tissues and becomes im-
portant in malignant cells of many human cancers types,
including breast cancer, ovarian cancer, melanoma, pros-
tate cancer and colorectal cancer [7]. Its ligand, CXCL12,
is constitutively and physiologically expressed in the liver,
lungs, lymph nodes and bone marrow [8,9]. CXCR7 is an-
other GPCR which also binds to CXCL12, but with a ten
fold greater affinity compared to CXCR4 [10]. Although
the role of CXCL12/CXCR7 signaling is not yet fully de-
scribed, this receptor seems to be essential for the survival
and growth of tumor cells [11-14].
Due to the crucial role of HIF-1α and CXCR4/CXCL12
in the metastatic process of colorectal cancer, we deter-
mined CXCR4 and CXCR7 gene expression in human
colon carcinomas and their modulation by hypoxia and
HIF-1α in colon cancer cell lines. We found that the
CXCR4 and CXCR7 expression levels increased propor-
tionally to the clinical stage and that hypoxia differentially
regulated the receptors. Furthermore, CXCR4 remained
stably expressed at the cell membrane after transient hyp-
oxia followed by 24 or 48 hours of normoxia. We also
found that inhibition of CXCR4 with siRNA or with the
CXCR4/CXCL12 neutraligand chalcone 4 significantly de-
creased the migration of these cells in vitro, an effect that
was amplified by concomitant inhibition of HIF-1α. Taken
together, these results indicate the potential of targeting
HIF-1α and CXCR4/CXCL12 in colorectal cancer.
Results
In vivo CXCR4 and CXCR7 expression in human
carcinomas
We measured CXCR4 and CXCR7 mRNA levels in human
polyps (n = 30) and carcinomas (n = 46). Tumor stages were
classified according to UICC (International Union Against
Cancer) recommendations (Table 1). The expression of
CXCR4 and CXCR7 mRNA in these tumors was compared
to that of a pool of healthy colonic mucosa samples. Over-
all, the expression levels of both CXCR4 and CXCR7 were
identical to those of the normal mucosa (Figure 1A-B).
In carcinomas, CXCR4 expression significantly increased
(p = 0.035) between early stage tumors (0-II) and late stage
tumors (III-IV) but without significance between stages
III-IV and metastases (p = 0.45) Figure 1C). CXCR7 ex-
pression significantly increased between early stage tumors
(0-II) and metastases (Figure 1D) (p = 0.02). Similarly, theCXCR4 and CXCR7 protein expression was absent in
polyps and early stages carcinomas but increased between
stage II and III, to be highest in the stage IV carcinomas
(Figure 2A-G). Expression was maintained in the liver me-
tastases (Figure 2H). Concerning CXCR7, a weak expres-
sion was found in the normal mucosa and stages I to IV,
which increased in the liver metastases due to increased
number of cells expressing CXCR7 (Figure 2I-K).
In vitro CXCR4 expression is regulated by HIF-1α
Transcript expression
We studied CXCR4 mRNA expression in normoxia (20%
O2) and hypoxia (3% or 1% O2) in SW480, HCT116 and
HT29 cells. In hypoxia, there was a significant increase in
CXCR4 mRNA level for the three cell lines (50 fold, 5.5
fold and 52.7 fold for SW480, HT29 and HCT116 cells re-
spectively) (Figure 3A) with a higher increase at 1% O2
than at 3% O2 (data not shown). On the other hand, as
compared to SW480 cells, HT29 and HCT116 cell lines
express low rates of CXCR7 (HT29 <HCT116 < SW480,
see Figure 4), and in SW480 cells, no change in CXCR7
mRNA level was observed between the normoxic and hyp-
oxic conditions (Figure 3B). To determine if the hypoxia-
related increase of CXCR4 mRNA expression is regulated
by HIF-1α, we used two different HIF-1α siRNAs. HIF-1α
mRNA expression was inhibited by 90% with both HIF-1α
siRNAs (Figure 3C), and CXCR4 expression was concomi-
tantly inhibited by more than 90% (Figure 3D).
Protein expression
We then studied the regulation of CXCR4 and CXCR7 pro-
tein expression at the cell membrane in hypoxia using flow
cytometry. For the three cell lines, hypoxia (1% 02) upregu-
lated the expression of CXCR4 protein at the cell mem-
brane, whereas CXCR7 expression remained unchanged
(Figure 4A), confirming the transcriptional data. The HIF-
1α and CXCR4 siRNAs led to decreased CXCR4 protein
expression, but not to the basal level observed in nor-
moxia (Figure 4B). These data demonstrate that hypoxia
induces a strong expression of CXCR4 at the cell mem-
brane that is regulated by HIF-1α, whereas CXCR7 ex-
pression is independent of hypoxia, HIF-1α and CXCR4.
Flow cytometry confirmed our previous observation
that CXCR7 is absent in the HCT116 and HT29 cells
but highly expressed in the SW480 cells.
Cell membrane CXCR4 expression after transient passage
in hypoxia
Within the tumor microenvironment, cells are subjected
to cycles of hypoxia/normoxia [15], whereas in the blood-
stream, they are exposed to normoxia. We hypothesized
that even after a transient passage through hypoxia, circu-
lating tumor cells, although exposed to normoxic condi-
tions in the bloodstream, will maintain CXCR4 expression
Table 1 Characteristics of adenomas and carcinomas
Adenomas Carcinomas
Mean Age (years) 66.5 ± 10.2 Mean Age (years) 66.1 ± 12
Number (n) Number (n)
Total Adenomas 30 Total Carcinomas 46
Men :Women 15 :11 Men :Women 33 :13
Localisation Proximal colon 14 Localisation Proximal colon 19
Distal colon 12 Distal colon 22
Metastasis 5
UICC classification Villous 1 UICC classification 0 (Tis) 2
Hyperplasia 0 I 7
Tubulovillous 2 II 12
Tubular 23 III 10
Grade High 6 IV 15
Low 20
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the CXCL12 gradient between the primary tumor site and
the liver. Flow cytometry allowed us to analyze CXCR4
expression in the colon cell lines cultured 24 hours in
hypoxia (1% O2) and further maintained for 8, 24 andFigure 1 CXCR4 and CXCR7 expression. A. CXCR4 expression in normal m
stages. C. CXCR7 expression in normal mucosa (n=), polyps (n = 30) and carci48 hours in normoxia. CXCR4 protein level remained
elevated at the cell membrane in the three cell lines for
8 to 24 hours. At 48 hours CXCR4 immunoreactivity
remained significantly higher in HT29 and SW480 cells
(Figure 4C).ucosa, polyps and carcinomas; B. CXCR4 expression according to UICC
nomas (n = 46); D. CXCR7 expression according to UICC stages. *p = 0.02.
Figure 2 CXCR4 and CXCR7 protein expression in human colon polyps, early and late stage carcinomas and metastases. Detection of CXCR4
protein expression assessed by immunohistochemical staining in representative specimens of polyp (B), primary stage I (C), II (D), III (E), IV (F) colon
tumours, metastatic liver (H1&H2) and corresponding non-cancerous neighbour colon (A), and liver (G) tissues. Detection of CXCR7 protein expression in
non-cancerous neighbour colon (I), primary stage IV colon tumor (J) and corresponding metastatic liver (K). Original magnification x200 (except H2, x400).
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by stimulation of the CXCR4/CXCL12 axis in vitro
Modulation by CXCL12
Our aim was to analyze the effect of CXCL12 stimulation
on the Akt and Erk oncogenic pathways. SW480 cells
were stimulated with 0.5 nM and 50 nM CXCL12. The
cells were starved for 4 h in a serum-free medium before
adding CXCL12, then maintained either in normoxia or inhypoxia (1%O2) and evaluated for protein kinase phos-
phorylation. In normoxia, both pathways were activated
with CXCL12 (Figure 5). This activation, however, was
weak as compared to that observed in hypoxia at 15 mi-
nutes, more specifically for the level of Akt phosphoryl-
ation (Figure 5). Increasing the CXCL12 concentration to
50 nM did not further enhance the level of Akt and Erk
phosphorylation (data not shown).
Figure 3 CXCR4 expression in different colon cell lines cultured in hypoxia. (A) Transcript CXCR4 expression in normoxia (20% O2) and
hypoxia (1% O2) in SW480, HCT116 and HT29 cell lines. (B) Transcript CXCR7 expression in normoxia (20% O2) and in hypoxia (3% and 1% O2) in
SW480 cell line. Trancript HIF-1α (C) and CXCR4 (D) expression after siRNA #1 or #2 anti-HIF-1α transfection; * p = 0.015; ** p = 0.001.
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To study the effect of CXCR4/CXCL12 axis inhibition
on Akt and Erk phosphorylation, the SW480 cell line
was treated with CXCR4 and CXCR7 siRNAs in hypoxia
(1% O2) in the presence of 0.5 nM CXCL12 for 15 mi-
nutes. Reducing CXCR4 expression impaired CXCL12-
induced Akt phosphorylation, whereas Erk activation
remained unchanged.
Simultaneously blocking the CXCL12-CXCR4 inter-
action with AMD3100 and inhibiting CXCR4 expression
with siRNA fully blocked CXCL12-induced Akt activation,
still without affecting Erk activation. Targeting CXCR7
and CXCL12/CXCR7 interaction affected neither Akt nor
Erk signaling (Figure 6A). Thus, the CXCL12/CXCR4 axis,
but not the CXCL12/CXCR7 axis, is able to modulate the
Akt pathway.
Therapeutic significance of targeting HIF-1α and CXCR4/
CXCL12 to prevent the dissemination process in vitro
The migration of SW480 cells was significantly increased
in hypoxia (4.6 fold at 3% and 5.8 fold at 1% O2) com-
pared to normoxia (p < 0.01) (Figure 6B). In the presence
of CXCR4 or CXCR7 siRNA, a significant reduction in cell
migration occurred (37% (p < 0.01) and 17%, respectively
(p < 0.01)) (Figure 6C). Treatment with both CXCR4 andCXCR7 siRNAs did not further decrease cell migration
(25.5% inhibition; p < 0.01).
Previous studies showed that irinotecan, a standard
chemotherapeutic drug for metastatic colon cancer, has
a cytostatic effect on xenografted colon tumors through
the inhibition of HIF-1α expression [16]. We also previ-
ously identified the compound chalcone 4 as a neutrali-
gand against CXCR4/CXCL12 interaction that blocks
CD4+ peripheral blood lymphocytes migration towards
CXCL12 [17]. Therefore, we decided to test the com-
bined effects of irinotecan and chalcone 4 on tumor cell
migration. First, the effect of increasing doses of chal-
cone 4 (0.1 μM, 1 μM and 10 μM) was measured on
SW480 cells migration under hypoxic conditions. Chal-
cone 4 at 1 μM and 10 μM reduced migration by 23%
and 80% (p <0.01), respectively (Figure 6D). Based on
these data, we used the combination of 1 μM chalcone 4
and 1 μM irinotecan (Figure 6E). These results clearly
show that chalcone 4 or irinotecan reduces cell mi-
gration by 20% at 1 μM. Upon co-treatment the
inhibition is further increased this inhibition to 40%
(p <0.001). These results thus demonstrate the sig-
nificance of inhibiting HIF-1α and the CXCR4/
CXCL12 interaction to affect the process of in vitro
cell dissemination.
Figure 4 Regulation of CXCR4 and CXCR7 protein expression at the cell membrane using flow cytometry. (A) CXCR4 and CXCR7
expression at the cell membrane of SW480, HCT116, and HT29, in normoxia (20% O2) and hypoxia (1% O2). (B) CXCR4 and CXCR7 expression in
SW480 cells after siRNA anti-HIF-1α or anti-CXCR4 in hypoxia. (C) Cell membrane CXCR4 protein expression after transient passage in hypoxia.
SW480, HCT116 and HT29 cells were cultured 24 hours in 3% hypoxia and further maintained for 8, 24 and 48 hours in normoxia.
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Analysis of a cohort of colon polyps and chromosome-
unstable carcinomas showed that the expression of CXCR4
and CXCR7 was similar to that of the normal mucosa in
the early-stage but significantly increased from early to late
stage carcinomas. Using three colon cell lines, we showed
that hypoxia was a strong activator of CXCR4 expression,
mainly through the involvement of HIF-1α, whereas
CXCR7, only expressed in SW480 cells, was not modulated
by hypoxia or HIF-1α. In addition, we showed for the first
time that after transient passage in hypoxia, CXCR4
remained expressed at the cell membrane when exposed to
normoxia for up to 48 hours. Finally, a novel combination
of an HIF-1α inhibitor (irinotecan) and a CXCL12-CXCR4
interaction inhibitor (chalcone 4) significantly impaired
the in vitro cell migration process. Although the migration
inhibition is only partial (40%), the fact that a higher chal-
cone concentration (10 μM) inhibits migration by 80%, is
clearly in favor of the involvement of CXCL12 via CXCR4
in the tumor cell migration process.Recent studies have reported on the overexpression of
the chemokine receptors CXCR4 and CXCR7 by several
tumor entities and have shown that CXCR4 plays a crucial
role in organ-specific metastasis formation [18]. However,
the precise mechanisms of chemokine receptor-driven
homing of cancer cells to specific sites of metastasis re-
main unclear.
Angiogenesis is critical to the growth, invasion, and
metastasis of human tumors [19,20]. Because targeting
angiogenesis has emerged as a promising strategy for the
therapeutic treatment of cancer, understanding the molecu-
lar mechanism linking tumor angiogenesis to the potential
of a tumor to disseminate has become very important. Dys-
regulation of HIF and/or cytokines, such as the CXCR4/
CXCR7/CXCL12 axis, is one probable cause of increased
angiogenesis via the overexpression of tumor VEGF. This
has led to the development of targeted therapies such as an
anti-VEGF antibody, recently approved for clinical use [21].
However, other mechanisms are most likely responsible for
tumor progression and dissemination, and the interaction
Figure 5 Activation of Akt and Erk oncogenic pathways by stimulation of CXCR4/CXCL12 axis in SW480 cell line. Effect of CXCL12
stimulation on Akt and Erk oncogenic pathways. SW480 cells were stimulated with CXCL12 at concentration of 0.5 nM. The cells cultivated either
in normoxia or in hypoxia (1%O2) and previously starved for 4 h in a serum-free medium before adding CXCL12, were evaluated for protein
kinase phosphorylation.
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play a major role in the settlement of colorectal tumor cells
in the liver [22]. Although CXCR4 expression is low or ab-
sent in normal tissues, CXCR4 is overexpressed in many
cancer types, including melanoma, breast, ovarian, prostate
and colorectal cancers [7,18]. In contrast, the chemokine
CXCL12, expressed at the surface of normal intestinal epi-
thelium [23], is decreased in tumor tissues, such as colon
or breast carcinomas [24,25]. As previously shown in glio-
blastoma cells, hypoxia and HIF-1α can regulate the ex-
pression of CXCR4 in colon cancer cell lines [26]. Others
have shown that hypoxia increases CXCR4 expression
through HIF-1α activation and that HIF-1α enhances the
expression and function of CXCR4 in normal cells mono-
cytes, macrophages and endothelial cells [27] and in tumor
cells [28]. In our hands, siRNAs targeting HIF-1α prevented
both HIF-1α and CXCR4 upregulation under hypoxic
conditions.
In human colon carcinomas, we observed that CXCR4
expression significantly increased during tumor progres-
sion as it increased from stages 0-II to III-IV, whereas
for CXCR7, a significant increase was observed between
early stages and liver metastases. Knowing that metastases
develop from circulating tumor cells escaping the primary
site of cancer during their passage in the blood stream
[29], these cells switch from a hypoxic to a normoxic en-
vironment and escape regulation by HIF-1α. Fitting with
this hypothesis, we demonstrated for the first time that
after a transient passage through hypoxia, which leads to
the upregulation of CXCR4 expression, the receptorprotein level remains high at the cell membrane even
when the cells returned back to normoxia. The mainten-
ance of high CXCR4 level could help circulating cells to
home in organs expressing high levels of the CXCL12
ligand, and with the resident CXCR7 may aid endothelial
extravasation favoring metastasis development [30,31]. Dur-
ing embryogenesis, it has been shown that CXCR7 is only
expressed in the trailing cells of the primordium and is re-
quired to provide migration directionality [32].
The CXCR4/CXCL12 interaction provokes calcium
mobilization and activation of multiple signaling path-
ways, including PI3K/Akt, PLC-γ/Protein kinase C and
Erk/Ras [33,34]. We show that hypoxia alone rapidly ac-
tivated the PI3K/Akt and Erk/Ras pathways and that this
effect was amplified under short-term CXCL12 stimula-
tion. Interestingly, part of the PI3K/Akt activation was
induced by the interaction of CXCL12 with CXCR4, as it
was blocked by siRNA targeting CXCR4, but not by its
interaction with CXCR7. As PI3K/Akt activation could
not be totally abolished with siRNA targeting CXCR4,
other receptors may participate in the activation of this
oncogenic pathway, although at present no other recep-
tors have been shown to interact with CXCL12. Neverthe-
less, the short-term activation of the oncogenic pathway
may be sufficient to initiate the migration process ob-
served when cells are switched to hypoxia, and this activa-
tion could be blocked with a siRNA against CXCR4.
Although CXCR4 inhibition with siRNA or AMD3100
affected the PI3K/Akt pathway, no change in activity was
observed for the Erk/Ras pathway. A number of the
Figure 6 Impact of CXCR4/CXCL12 axis inhibition in SW480 cell line. (A) Effect of CXCR4/CXCL12 axis inhibition on Akt and Erk
phosphorylation. Cells are treated with CXCR4 and CXCR7 siRNAs in hypoxia (1% O2) in presence of 0.5 nM CXCL12 for 15 minutes with or
without the CXCR4 antagonist AMD 3100 (10 μM). (B) SW480 cell migration in hypoxia (3% and 1% O2) using a Boyden chamber assay. After
24 h incubation, cells remaining on the upper chamber are mechanically removed. The cells that have migrated to the lower chamber are
counted after staining with fluorescent dye (DAPI or 4',6-diamidino-2-phenylindole). Quantification was performed by microscope counting five
random fields for each chamber (* p < 0.001). (C) SW480 cell migration was analyzed in presence of CXCR4 or CXCR7 siRNA. There was a
significant reduction in migration (37% and 17%, respectively. (D) The effect of increasing doses of chalcone 4 (0.1 μM, 1 μM and 10 μM) was
measured on cells migrating under hypoxic conditions. Chalcone 4 at 1 μM and 10 μM reduced migration by 23% and 80%, respectively. (E)
Effect of the combination of chalcone 4 and irinotecan at 1 μM. Although irinotecan inhibited migration by 20% (*p <0.01), the irinotecan and
chalcone 4 combination further increased the inhibition to 40% (**, p = 0.001).
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deregulated in a wide variety of human tumors, highlight-
ing the key role of this pathway in cellular transform-
ation [35]. Following Akt phosphorylation, the
subsequent phosphorylation of its targets regulates a
variety of critical cell functions, including glucose metab-
olism, cell proliferation and survival. PI3K also is likely im-
plicated in the metastatic phenotype. Indeed, several
molecules involved in cell migration and cell adhesion can
regulate -or be regulated by- PI3K. Indeed, PI3K/Akt was
shown to be essential for Matrix Metalloproteinase (MMP)
production in several cell lines [36] and clinical and animal
studies revealed that PI3K/Akt activates MMP-2, MMP-9,and Urokinase-type plasminogen activator (uPA), leading
to destruction of the extracellular matrix [37]. Other data
might explain our observation of inhibition of cell migra-
tion with CXCR4 inhibitors. Gassmann and colleagues for
instance, demonstrated that colon cell line extravasation
into the liver parenchyma is regulated in vivo by CXCL12-
activated CXCR4 [30]. In contrast, we found that CXCR7
silencing did not modify the migration process or the acti-
vation of the PI3K/Akt or Erk/Ras pathway. This is consist-
ent with recent studies providing alternative mechanisms
through which CXCR7 can regulate CXCL12-directed cell
movement. CXCR7 does not appear to induce cell migra-
tion directly but may enhance cell adhesion [11], and the
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dothelial migration of human renal multipotent progenitor
cells has been demonstrated [12]. Additionally, Zabel et al
showed that CXCR7, through association with β-arrestin
but without Ca2+ mobilization, regulates the ability of hu-
man CXCR7+/CXCR4+ lymphoblastoid cells to migrate
across an endothelial cell monolayer [38].
HIF-1α is frequently upregulated at protein level in re-
sponse to the hypoxic tumor environment and this overex-
pression has been associated with an aggressive phenotype,
namely resistance to chemotherapy and poor outcome in a
wide range of tumors [3]. One hypothesis concerning the
metastatic process is based on an increasing CXCL12
gradient from the primary tumor to secondary niches at
metastatic sites. Immunohistochemical analyses have
shown that CXCL12 is highly expressed in hepatic sinu-
soids including endothelial and Kupffer cells [38] and that
disseminating tumor cells express CXCR4 [7]. Thus,
the CXCL12/CXCR4 interaction permits extravasation
of colon tumor cells in the liver parenchyma [36].
Moreover, CXCR4/CXCL12 interaction increases the ex-
pression of proteins important for cell migration, motility
and invasion, such as Rho and Rac [39-41].
Altogether, our results demonstrate the potential value
of inhibiting HIF-1α and CXCR4/CXCL12 to counteract
the migration process. We have used an innovative ap-
proach to impair tumor cell migration by combining irino-
tecan and chalcone 4 that could be of therapeutic interest.
We have previously shown that irinotecan inhibited HIF-
1α protein accumulation in in vitro [42] and in vivo models
of colon cancer [16,42]. We hypothesized that irinotecan
would inhibit CXCR4 expression by inhibiting HIF-1α.
Chalcone 4 is a neutraligand of CXCL12 and impairs
CXCR4/CXCR7/CXCL12 interaction. In addition, other
studies have already shown that inhibition of CXCR4
in vivo inhibits the metastatic process and the migration of
breast cancer cells. We have shown that the combination
of the two drugs is more effective than each drug separ-
ately as migration was decreased by more than 40%.Conclusion
We have demonstrated for the first time the potential
therapeutic significance of inhibiting CXCR4 signaling
through a combinatorial approach inhibiting HIF-1α and
CXCR4/CXCL12 interaction. CXCR4 seems to be a rele-
vant target, as CXCR4 remains continuously expressed
when tumor cells switch from a hypoxic to a normoxic
environment. Finally, CXCR7 is differentially expressed
compared to CXCR4 and could be involved in some
subtypes of more aggressive tumors. Thus, CXCR4 and
CXCR7 seem to play different roles in colon tumors, and
further studies are necessary to better understand their re-
spective roles.Materials and methods
Tumor specimens
Human tumor specimens were obtained at the Gastro-
intestinal Surgical Department of the University Hospital
Hautepierre (Strasbourg-France) according to the French
Ethical Committee recommendations and the ethical
standards of the 1964 Declaration of Helsinki. All pa-
tients provided written informed consent.
Cell culture and treatments
Human colon carcinoma HCT-116, HT-29 and SW480
cells were maintained at 37°C under normoxic (20% O2)
and hypoxic conditions (94% N2, 5% CO2, 3 or 1% O2,
Sanyo) in DMEM (1 g/L glucose) supplemented with 10%
fetal bovine serum. The cells were treated during expo-
nential growth conditions (30% confluence).
Irinotecan (Campto®, irinotecan chlorydrate, Pfizer)
was used at a concentration of 1 μM. AMD3100 (Sigma
France), an antagonist of CXCR4, was used at 10 μM.
Chalcone 4 was provided by JL Galzi (ESBS, Strasbourg,
France); [17].
SiRNA transfections
The cells were transfected in 6-well plates with siRNA
anti-HIF-1α (20 nM; siRNA 1: Hs_HIF-1α_5: SI02664053,
siRNA 2: Hs_ HIF-1α_6: SI02664431, Qiagen®) and anti-
CXCR4 (20 nM; siRNA 1: Hs_CXCR4 7: SI02664235 and
siRNA 2: Hs_CXCR4 8: SI02664242, Qiagen®) with the
Lipofectamine® RNAiMAX, (Invitrogen®, Life Technolo-
gies) according to the manufacturer’s instructions. A
non-specific, non-targeting siRNA was used as the control
treatment (Eurogentec®). The cells were incubated for
48 h at 37°C in hypoxia (94% N2, 5% CO2, 3 or 1% O2,
Sanyo®).
Migration tests
Boyden chambers (BD Biosciences) were used for the
in vitro migration assay. The upper and lower compart-
ments were filled with 1% FCS and 10% FCS, respectively.
Cells (5 × 105) were added in the upper compartment.
After 24 h, the cells were fixed with 4% paraformaldehyde
for 15 min and stained with DAPI (1/30000; 4', 6'-diami-
dino-2-phenyl indole, Sigma®). Migrating cells were
counted using an epifluorescence microscope.
Relative quantitative PCR
The mRNA expression of CXCR4, CXCR7, HIF-1α and
control PDGF genes was evaluated by relative quantita-
tive real-time PCR (RT-qPCR) analysis using the Light-
Cycler system (Roche Molecular Biochemicals®) and
FastStart DNA Master Mix SYBR Green I (Roche Diagnos-
tics®). RNA was extracted with Trizol reagent (Invitrogen®)
according to the manufacturer's protocol. Reverse tran-
scription of 2 μg RNA was performed using reverse
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performed as follows: denaturation at 95°C for 10 min, fol-
lowed by 40 cycles at 95°C for 20 s and 62°C for 20 s and
elongation at 72°C for 20 s using the maximum temper-
ature transition rate of 20°C/s. Fluorescence measurements
were taken at the end of the elongation phase. The specifi-
city of the PCR products was assessed by generating a melt-
ing curve. All quantifications were performed in duplicate
for three independent experiments and normalized with re-
spect to the endogenous PDGF mRNA levels. Target cDNA
expression was quantified using the ΔΔCt method. Vali-
dated primers were obtained from Qiagen®.
Western Blot
Western Blots were performed with the following anti-
bodies: anti-Akt total (1/1000), anti-Erk total (1/2000),
anti-phospho Akt (1/1000), anti-phospho-Erk (1/1000)
(from Cell Signaling Technology ®), anti-HIF-1alpha (1/
1500, BD Biosciences®), anti-actin (1/15000, Millipore ®).
Flow cytometry
For each condition, 106 cells were washed in PBS 1X at
4°C. Fluorescence was analyzed on a FACScan cytometer
(BD Biosciences®), and the data were analyzed with
CellQuest (BD Biosciences®). The measurements were
performed twice in two independent experiments.
Immunohistochemistry
Immunohistochemistry used standard procedures. Briefly,
tumors were fixed in 4% paraformaldehyde and embedded
in paraffin. Sections (4 μm) were deparaffinized and heated
for 10 minutes in 10 mmol/L citrate buffer, pH 6.2, for
antigen retrieval. They were stained with Harris solution
and Eosin for histological examination and immunostained
using the primary antibodies raised against CXCR4 (1:200;
eBiosciences) and CXCR7 (1:75; ThermoScientific). Slides
were then incubated for 30 min with secondary biotinylated
anti-mouse antibody (dilution 1:200; Vector Laboratories
Inc., Burlingame, CA). Immunostaining was developed with
a liquid DAB substrate kit (Roche Diagnostics) according to
the manufacturer’s instructions.
Statistics
The data were analyzed with the Mann–Whitney para-
metric test, and the significance level was set at 5%.
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